Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$28.09 USD
+0.55 (2.00%)
Updated May 17, 2024 04:00 PM ET
After-Market: $28.12 +0.03 (0.11%) 6:10 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Brokerage Reports
0 items in cart
Corcept Therapeutics Incorporated [CORT]
Reports for Purchase
Showing records 21 - 40 ( 220 total )
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Multiple Clinical Data Readouts Expected in 2024; PT Up To $34; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Korlym Revenue Higher Than Expected; Key Catalysts Center on Relacorilant; New $32 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Miricorilant NASH Data Could be the Next Catalyst; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Cushings Syndrome Franchise to Remain Strong in 2023 and Beyond; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Miricorilant Misses on AIWG; Reiterate Buy; Lower PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S